Henry Schein, Inc. (NASDAQ:HSIC) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have been assigned a consensus rating of “Hold” from the eleven research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $81.73.

Several research analysts have recently weighed in on HSIC shares. JPMorgan Chase & Co. increased their price objective on shares of Henry Schein from $82.00 to $88.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Barrington Research increased their price target on shares of Henry Schein from $90.00 to $92.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 8th. UBS Group lowered their price objective on shares of Henry Schein from $82.00 to $80.00 and set a “neutral” rating for the company in a research note on Wednesday, May 8th. Piper Sandler reaffirmed an “overweight” rating and issued a $86.00 target price on shares of Henry Schein in a research report on Friday, June 21st. Finally, Jefferies Financial Group lifted their target price on Henry Schein from $74.00 to $81.00 and gave the company a “hold” rating in a report on Wednesday, March 6th.

Henry Schein Trading Up 0.0 %

Shares of HSIC opened at $64.10 on Tuesday. Henry Schein has a fifty-two week low of $60.01 and a fifty-two week high of $82.63. The company has a market capitalization of $8.21 billion, a PE ratio of 21.66, a price-to-earnings-growth ratio of 1.58 and a beta of 0.90. The stock has a fifty day moving average of $69.91 and a two-hundred day moving average of $72.89. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.02 and a current ratio of 1.75.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.09. Henry Schein had a return on equity of 13.51% and a net margin of 3.12%. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.21 billion. During the same quarter in the previous year, the business earned $1.21 earnings per share. The business’s revenue for the quarter was up 3.7% on a year-over-year basis. As a group, analysts forecast that Henry Schein will post 5.16 EPS for the current year.

Institutional Investors Weigh In On Henry Schein

Institutional investors and hedge funds have recently modified their holdings of the stock. Swedbank AB purchased a new stake in shares of Henry Schein during the 1st quarter valued at about $215,998,000. Wahed Invest LLC raised its stake in shares of Henry Schein by 14.3% during the first quarter. Wahed Invest LLC now owns 2,540 shares of the company’s stock valued at $192,000 after purchasing an additional 318 shares during the period. Tidal Investments LLC raised its stake in shares of Henry Schein by 21.4% during the first quarter. Tidal Investments LLC now owns 5,632 shares of the company’s stock valued at $425,000 after purchasing an additional 994 shares during the period. California State Teachers Retirement System lifted its position in shares of Henry Schein by 1.7% during the first quarter. California State Teachers Retirement System now owns 212,108 shares of the company’s stock worth $16,018,000 after purchasing an additional 3,534 shares in the last quarter. Finally, Magnetar Financial LLC boosted its stake in shares of Henry Schein by 229.9% in the first quarter. Magnetar Financial LLC now owns 386,458 shares of the company’s stock valued at $29,185,000 after purchasing an additional 269,330 shares during the period. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.